Hyphens Pharma International Limited has announced an agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to exclusively register and commercialise the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam.
This device is used for treating rheumatoid arthritis and plaque psoriasis, offering a convenient two-step self-injection with a built-in needle cover for enhanced safety.
The Metoject® pen administers methotrexate, a first-line treatment for rheumatoid arthritis, ensuring high bioavailability and reduced gastrointestinal side effects compared to oral administration. Available in multiple strengths, it allows for tailored treatment options. The pen has already been commercialised in over 15 countries, including the US and Japan.
Frank Lucaßen, CEO of medac, expressed confidence in Hyphens Pharma’s capabilities, stating, “We were looking for a partner in Southeast Asia with strong regulatory and sales and marketing capabilities, and Hyphens Pharma clearly stood out.” Lim See Wah, Chairman and CEO of Hyphens Pharma, added, “We are delighted to work with Medac to bring Metoject® to Southeast Asia as it provides an effective, safe and convenient treatment benefitting rheumatoid arthritis and plaque psoriasis patients in the region.”
This agreement is not expected to materially affect Hyphens Pharma’s financials for the year ending 31 December 2025. The move marks a significant expansion of Hyphens Pharma’s Speciality Pharma portfolio, enhancing treatment options for rheumatologists and dermatologists in the ASEAN region.
“`
This news story was carefully selected and published by a human editor, though the content itself was AI-generated. If you spot an error, please report it here.
